1. Introduction {#s0005}
===============

LHA (*Leonurus japonicus* Houtt.) is also known as winds, Vallisneri. Research findings have shown that motherwort contains effective components of total alkaloids (total alkaloids) ([@b0020]). LHA mainly includes Leonurine and stachydrine hydrochloride and other ingredients, according to TCM treatment of uroschesis "certificate" of the main treatment. LHA has the effect of detoxification, blood circulation, and diuresis. Pharmacological studies show that LHA can improve blood rheology and microcirculation and has the functions such as anti-inflammatory and analgesic, anti oxygen free radical, potassium sparing diuretic, enhance immunity and protection of myocardial.

2. Material {#s0010}
===========

2.1. Animal {#s0015}
-----------

Rat, SD, male (270--300 g), male (540--630 g), provided by the experimental animal center of Shandong Province, Qualification No.: 0019881; Laboratory Certificate No.: SYXK (Lu) 2013001.

2.2. Drugs and reagents {#s0020}
-----------------------

LHA, Baoji Guokang Biological Technology Co. Ltd., concentration \>80%, Production Batch No.: 20090615; Longbishu capsule, Shijiazhuang Kedi Pharmaceutical Co. Ltd., production Batch No.: 130706; Finasteride Capsules, Wuhan Humanwell Pharmaceutical LLC, Production Batch No.:20140202; Testosterone Propionate Injection, Shanghai GM Pharmaceutical Holdings C., Ltd, Production Batch No.: 130614; Estradiol Benzoate Injection, Harbin Three Beast Horse Industry Co., Ltd, Production Batch No.: 20131001; Benzylpenicillin Sodium for Injection, North China Pharmaceutical Co., ltd, specifications: 400 units, Production Batch No.: C1406807; Dihydrotestosterone (DHT) kit, Estradiol (E2) kit, Testosterone (T) kit, Prostatic acid phosphatase (PACP) kit, American R&D company, Production Batch No.: 20140702B.

2.3. Instrument {#s0025}
---------------

Type 680 eliasa, America BIO-RAD; UV1000 type UV VIS spectrophotometer, manufacturer: Shanghai Techcomp Instrument Co. Ltd.; KDC-160HR type high speed refrigerated centrifuge, manufacturer: Zhongjia Branch of KDCX Holdings Co., Ltd.

3. Method {#s0030}
=========

3.1. Experimental grouping {#s0035}
--------------------------

Take 70 clean grade male SD rats aged 18 months, and take another 10 young rats (250--270 g) as a young control group. The eighteen-month old rats were randomly divided into 7 groups (10 in each group), and one of the groups was the control group, the other 6 groups of aged BPH model rats were divided into the model group, the Longbishu control group, the Finasteride group, and the small, middle, and large dose LHA group.

3.2. Modeling and administration {#s0040}
--------------------------------

The model rats should be removed of bilateral testes, after intraperitoneal injection of 10% hydrate (0.3 ml/100 g), suture skin, and intramuscular inject of penicillin 200 thousand μ/kg, 1 time a day, 7 times a day, which continued for 30d ([@b0015]). On the first day of surgery, for the large, middle small dose LHA (50 mg/kg, 25 mg/kg, 12.5 mg/kg), Longbishu suspension (dose equivalent to 10 times the clinical dosage), Finasteride (dose equivalent to 10 times the clinical dosage), feed the rats equal volume of distilled water.

On the 27th day, all animals were operated on bladder stoma. PE pipeline with normal saline was fixed to the bladder at the top of the bladder with the method of purse string suture (5--0 silk thread). The other port of PE pipe was fixed on the back of the neck of rats through rat skin. On the 30th day, cut the line on the back of the rat\'s neck and take out the PE pipe which was fixed on the back of the rat's neck and connect it to the urine flow dynamics instrument. After adaptation for about 1 h, the rats were fed sterile saline solution for 2 h at the rate of 120 μl/min, and 3 micturition peak data were collected. After detection, weigh the rats, take the eyeball blood, determine serum E2 levels, and quickly remove the prostate, thymus gland, spleen, kidney, lung, and bladder. 1/3 prostate homogenate was used for determining the level of PACP, T, DHT. 1/3 prostate was used for determination of mRNA expression in bFGF. The remaining 1/3 prostate was observed by light microscopy.

4. Statistical analysis {#s0045}
=======================

SPSS17.0 was used for statistical processing, and measurement data were expressed by $(\overline{\text{x}} \pm \text{s})$, comparison of the single factor analysis of variance. Homogeneity of variance test was conducted using the LSD method. The variance was tested with Games--Howell method.

5. Result {#s0050}
=========

5.1. Effect of LHA on urine flow dynamics on aged BPH model rats (Male and female hormone induced) {#s0055}
--------------------------------------------------------------------------------------------------

Compared with the blank group of aged rats, the voiding peak pressure, the micturition interval, and the bladder pressure of the rats significantly increased in model group. Compared with the model group, the maximum pressure of micturition, micturition interval, bladder pressure (*p* \< 0.01) of the rats in the Finasteride group, the Longbishu group, and the LHA large, small and middle groups significantly decreased ([Table1](#t0005){ref-type="table"}).

5.2. Effect of LHA on the level of T in the prostate tissue, and E2 in serum on aged BPH model rats (Male and female hormone induced) {#s0060}
-------------------------------------------------------------------------------------------------------------------------------------

Compared with the blank group of aged rats, the level of T and E2 significantly increased in the model group (*p* \< 0.01). Compared with the model group, the level of T and E2 (*p* \< 0.01) significantly decreased in the Finasteride group, the Longbishu group, and large, middle, small dose groups of LHA ([Table2](#t0010){ref-type="table"}).

5.3. Effect of LHA on the expression of mRNA in prostate bFGF on aged BPH model rats (Male and female hormone induced) {#s0065}
----------------------------------------------------------------------------------------------------------------------

Compared with the blank group of aged rats, the expression of mRNA in bFGF was significantly higher in the model group (*p* \< 0.01). Compared with the model group, the expression of mRNA in bFGF significantly decreased in the Finasteride group, the Longbishu group, and the large dose of LHA group ([Table3](#t0015){ref-type="table"}).

5.4. Effect of LHA on the level of DHT, PACP on aged BPH model rats(Male and female hormone induced) {#s0070}
----------------------------------------------------------------------------------------------------

Compared with the blank group of aged rats, the level of DHT and the content of PACP in model group significantly increased (*p* \< 0.01). Compared with the model group, the level of DHT and PACP (*p* \< 0.01) in the Finasteride group, the Longbishu group, and the large, middle, small dose of LHA group significantly decreased ([Table4](#t0020){ref-type="table"}).

6. Discussion {#s0075}
=============

In this experiment, the rat model of BPH was established through subcutaneous injection of testosterone and estradiol in removed bilateral testes of rats ([@b0005]). Abnormal micturition is the most common clinical symptoms in patients with BPH ([@b0035]). The normal micturition process involves the bladder and the urethra. With BPH in the elderly forced structure, the change of function of the bladder and urethra, might lead to lower urinary tract symptoms. Therefore, through the determination of rat bladder pressure, the intercontraction interval was alleviated in BPH model of rats. The changes in the clinical index could also be the most intuitive reaction for the improvement of LHA to the BPH model rats. Testosterone (T) is the main androgen in the human body ([@b0010]). It is on the 5 alpha reductase function into dihydrotestosterone (DHT). The increase in the DHT level in the prostate could lead to BPH. Basic fibroblast growth factor (b-FGF) plays a role in the regulation by DHT and could be called a regulatory growth factor ([@b0025]). It could lead to proliferation of epithelial cells of the prostate gland, causing the cavity to become larger and the secretion to increase, thus generating BPH ([@b0045]).

Leonuri Herba is a common medicine for activating blood circulation, and it is called "the holy blood family" in the *Compendium of Materia Medica* ([@b0030]). It is regarded as the cure for diseases in the department of gynecology. Modern pharmacological studies show that it contains a wide range of active ingredients with a variety of pharmacological effects and is able to be used for treating a variety of diseases. The functions of promoting blood circulation and removing blood stasis, clearing away heat and toxic materials, and diuresis with Leonuri Herba, accord with the treatment mechanism of BPH. The main component of Leonuri Herba is stachydrine and leonurine, and they are the main ingredients used to treat BPH ([@b0040]).

This experiment shows that large, small doses of LHA group could significantly reduce the maximum voiding pressure, the intercontraction interval, the bladder resting pressure, significantly reduce DHT, T, PAC in the prostate homogenate, significantly elevate serum E2 levels, and significantly reduce the expression of mRNA in the prostate of bFGF. The effect of LHA on BPH model rats was very good. This study has provided experimental support for the clinical treatment of LHA to BPH, and also provided new ideas and methods for the prevention and treatment of BPH.
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###### 

Effect of LHA on urine flow dynamics on aged BPH model rats (Male and female hormone induced).

  Group                      N    Voiding peak pressure                               Urine interval                                     Urinary bladder resting pressure
  -------------------------- ---- --------------------------------------------------- -------------------------------------------------- -----------------------------------------------------
  Youth blank group          10   32.68 ± 2.14[\*\*](#tblfn1){ref-type="table-fn"}    9.525 ± 1.05[\*\*](#tblfn1){ref-type="table-fn"}   504.77 ± 59.69[\*\*](#tblfn1){ref-type="table-fn"}
  Aged blank group           10   56.93 ± 14.06[\*\*](#tblfn1){ref-type="table-fn"}   9.58 ± 0.99[\*\*](#tblfn1){ref-type="table-fn"}    506.62 ± 65.26[\*\*](#tblfn1){ref-type="table-fn"}
  Model group                10   90.66 ± 8.14[△△](#tblfn2){ref-type="table-fn"}      13.94 ± 2.65[△△](#tblfn2){ref-type="table-fn"}     1455.934 ± 287.80[△△](#tblfn2){ref-type="table-fn"}
  Finasteride group          10   68.82 ± 7.31[\*\*](#tblfn1){ref-type="table-fn"}    10.21 ± 1.15[\*\*](#tblfn1){ref-type="table-fn"}   543.76 ± 81.49[\*\*](#tblfn1){ref-type="table-fn"}
  Longbishu group            10   60.27 ± 3.43[\*\*](#tblfn1){ref-type="table-fn"}    10.34 ± 1.30[\*\*](#tblfn1){ref-type="table-fn"}   562.64 ± 102.69[\*\*](#tblfn1){ref-type="table-fn"}
  Large dose of LHA group    10   62.560 ± 3.97[\*\*](#tblfn1){ref-type="table-fn"}   10.92 ± 1.62[\*\*](#tblfn1){ref-type="table-fn"}   723.35 ± 116.06[\*\*](#tblfn1){ref-type="table-fn"}
  Middle dose of LHA group   10   65.33 ± 8.57[\*\*](#tblfn1){ref-type="table-fn"}    10.77 ± 0.99[\*\*](#tblfn1){ref-type="table-fn"}   792.78 ± 138.57[\*\*](#tblfn1){ref-type="table-fn"}
  Small dose of LHA group    10   70.63 ± 6.48[\*\*](#tblfn1){ref-type="table-fn"}    10.88 ± 0.74[\*\*](#tblfn1){ref-type="table-fn"}   813.65 ± 139.65[\*\*](#tblfn1){ref-type="table-fn"}

Indicate: compared with model group *p* \< 0.01.

Indicate: compared with the blank group in the elderly.

###### 

Effect of LHA on the level of T, E2 in serum on aged BPH model rats (Male and female hormone induced).

  Group                      N    T (pg/ml)                                            E2 (pmol/L)
  -------------------------- ---- ---------------------------------------------------- --------------------------------------------------
  Youth blank group          10   65.61 ± 31.40[\*\*](#tblfn3){ref-type="table-fn"}    9.98 ± 2.10[\*\*](#tblfn3){ref-type="table-fn"}
  Aged blank group           10   134.90 ± 48.17[\*\*](#tblfn3){ref-type="table-fn"}   19.68 ± 4.92[\*\*](#tblfn3){ref-type="table-fn"}
  Model group                10   327.14 ± 16.40[△△](#tblfn4){ref-type="table-fn"}     32.92 ± 3.44[△△](#tblfn4){ref-type="table-fn"}
  Finasteride group          10   200.41 ± 17.65[\*\*](#tblfn3){ref-type="table-fn"}   26.57 ± 2.72[\*\*](#tblfn3){ref-type="table-fn"}
  Longbishu group            10   203.37 ± 14.32[\*\*](#tblfn3){ref-type="table-fn"}   26.95 ± 1.33[\*\*](#tblfn3){ref-type="table-fn"}
  Large dose of LHA group    10   215.82 ± 19.84[\*\*](#tblfn3){ref-type="table-fn"}   27.11 ± 4.43[\*\*](#tblfn3){ref-type="table-fn"}
  Middle dose of LHA group   10   222.24 ± 8.40[\*\*](#tblfn3){ref-type="table-fn"}    27.35 ± 1.94[\*\*](#tblfn3){ref-type="table-fn"}
  Small dose of LHA group    10   226.94 ± 8.41[\*\*](#tblfn3){ref-type="table-fn"}    27.73 ± 2.71[\*\*](#tblfn3){ref-type="table-fn"}

Indicate: compared with model group p \< 0.01.

Indicate: compared with the blank group in the elderly.

###### 

Effect of LHA to the expression of mRNA in Prostate bFGF on aged BPH model rats (Male and female hormone induced).

  Group                      N    mRNA-bFGF
  -------------------------- ---- ------------------------------------------------------
  Youth blank group          10   0.0297 ± 0.02068[\*\*](#tblfn5){ref-type="table-fn"}
  Aged blank group           8    0.0176 ± 0.00654[\*\*](#tblfn5){ref-type="table-fn"}
  Model group                3    0.0733 ± 0.01057[△△](#tblfn6){ref-type="table-fn"}
  Finasteride group          8    0.0377 ± 0.01111[\*\*](#tblfn5){ref-type="table-fn"}
  Longbishu group            8    0.0376 ± 0.01756[\*\*](#tblfn5){ref-type="table-fn"}
  Large dose of LHA group    16   0.0354 ± 0.01472[\*\*](#tblfn5){ref-type="table-fn"}
  Middle dose of LHA group   6    0.0571 ± 0.01637
  Small dose of LHA group    6    0.0453 ± 0.01674

Indicate: compared with model group p \< 0.01.

Indicate: compared with the blank group in the elderly.

###### 

Effect of LHA to the level of DHT, PACP on aged BPH model rats (Male and female hormone induced).

  Group                      N    DHT (nmol/L)                                       PACP (pg/ml)
  -------------------------- ---- -------------------------------------------------- -----------------------------------------------------
  Youth blank group          10   13.93 ± 1.94[\*\*](#tblfn7){ref-type="table-fn"}   579.50 ± 184.86[\*\*](#tblfn7){ref-type="table-fn"}
  Aged blank group           10   17.51 ± 1.27[\*\*](#tblfn7){ref-type="table-fn"}   707.55 ± 84.32[\*\*](#tblfn7){ref-type="table-fn"}
  Model group                10   35.29 ± 3.11[△△](#tblfn8){ref-type="table-fn"}     1436.00 ± 170.79[△△](#tblfn8){ref-type="table-fn"}
  Finasteride group          10   19.69 ± 1.74[\*\*](#tblfn7){ref-type="table-fn"}   820.80 ± 32.88[\*\*](#tblfn7){ref-type="table-fn"}
  Longbishu group            10   19.84 ± 1.16[\*\*](#tblfn7){ref-type="table-fn"}   834.55 ± 46.90[\*\*](#tblfn7){ref-type="table-fn"}
  Large dose of LHA group    10   20.98 ± 1.40[\*\*](#tblfn7){ref-type="table-fn"}   851.30 ± 66.03[\*\*](#tblfn7){ref-type="table-fn"}
  Middle dose of LHA group   10   21.19 ± 1.81[\*\*](#tblfn7){ref-type="table-fn"}   895.60 ± 61.08[\*\*](#tblfn7){ref-type="table-fn"}
  Small dose of LHA group    10   17.51 ± 1.29[\*\*](#tblfn7){ref-type="table-fn"}   926.25 ± 127.53[\*\*](#tblfn7){ref-type="table-fn"}

Indicate: compared with model group p \< 0.01.

Indicate: compared with the blank group in the elderly.
